B
Bioarctic
Swedish research-oriented biopharma company
About Bioarctic
BioArctic is a Swedish biopharmaceutical company dedicated to developing disease-modifying treatments and reliable diagnostics for neurodegenerative diseases, including Alzheimer's and Parkinson's. The company also focuses on potential treatments for Complete Spinal Cord Injury. Operating in the biopharma sector, BioArctic serves patients, healthcare providers, and research institutions. Its business model revolves around research and development, leveraging partnerships and collaborations to advance its pipeline. Revenue is generated through licensing agreements, collaborations, and potential product sales. BioArctic addresses high unmet medical needs by targeting the underlying pathology of diseases, aiming to halt disease progression and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2003
- Headquarters
- Stockholm, Sweden
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series B and later1 investor entered at this stage
EQT Life Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
24 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bioarctic on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bioarctic on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.